These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22125312)

  • 41. Contribution of polymeric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis.
    Murthy AK; Dubose CN; Banas JA; Coalson JJ; Arulanandam BP
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1372-80. PubMed ID: 16911679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD26 and DPP IV expression in T acute lymphoblastic leukemia cells: immunocytochemistry and enzyme cytochemistry.
    Klobusická M; Babusíková O
    Gen Physiol Biophys; 1999 Dec; 18 Suppl 1():34-7. PubMed ID: 10707830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines.
    Gay J; Kokkotou E; O'Brien M; Pothoulakis C; Karalis KP
    Neuroimmunomodulation; 2006; 13(2):114-21. PubMed ID: 17077645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucose regulation of dipeptidyl peptidase IV gene expression is mediated by hepatocyte nuclear factor-1alpha in epithelial intestinal cells.
    Gu N; Tsuda M; Matsunaga T; Adachi T; Yasuda K; Ishihara A; Tsuda K
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1433-9. PubMed ID: 18671716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: possible implications for the hypothalamic neuropeptidergic system.
    Stephan M; Radicke A; Leutloff S; Schmiedl A; Pabst R; von Hörsten S; Dettmer S; Lotz J; Nave H
    Behav Brain Res; 2011 Jan; 216(2):712-8. PubMed ID: 20887754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis.
    Tokuyama H; Ueha S; Kurachi M; Matsushima K; Moriyasu F; Blumberg RS; Kakimi K
    Int Immunol; 2005 Aug; 17(8):1023-34. PubMed ID: 16000328
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy.
    Aytac U; Dang NH
    Curr Drug Targets Immune Endocr Metabol Disord; 2004 Mar; 4(1):11-8. PubMed ID: 15032621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dipeptidyl peptidase IV (DPP IV, CD26) in patients with mental eating disorders.
    Hildebrandt M; Rose M; Mayr C; Arck P; Schüler C; Reutter W; Salama A; Klapp BF
    Adv Exp Med Biol; 2000; 477():197-204. PubMed ID: 10849747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD26/DPP IV in experimental and clinical organ transplantation.
    Korom S; de Meester I; Belyaev A; Schmidbauer G; Schwemmle K
    Adv Exp Med Biol; 2003; 524():133-43. PubMed ID: 12675233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.
    Buljevic S; Detel D; Pucar LB; Mihelic R; Madarevic T; Sestan B; Varljen J
    Rheumatol Int; 2013 Nov; 33(11):2867-74. PubMed ID: 23864142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity of Dipeptidyl Peptidase-IV/CD26 and Aminopeptidase N/CD13 in Secretome of Mesenchymal Stem Cells after Treatment with LPS and PMA.
    Ramezani Ali Akbari K; Fathollahi A; Hashemi SM; Pouriran R; Yeganeh F
    Iran J Immunol; 2020 Mar; 17(1):41-51. PubMed ID: 32224540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of CD26/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis.
    Yeganeh F; Mousavi SMJ; Hosseinzadeh-Sarband S; Ahmadzadeh A; Bahrami-Motlagh H; Hoseini MHM; Sattari M; Sohrabi MR; Pouriran R; Dehghan P
    Clin Rheumatol; 2018 Dec; 37(12):3183-3190. PubMed ID: 30136129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients.
    Uematsu T; Urade M; Yamaoka M
    J Oral Pathol Med; 1998 Mar; 27(3):106-10. PubMed ID: 9563801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.
    Vora KA; Porter G; Peng R; Cui Y; Pryor K; Eiermann G; Zaller DM
    BMC Immunol; 2009 Apr; 10():19. PubMed ID: 19358731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Further characterization of DPP IV-beta, a novel cell surface expressed protein with dipeptidyl peptidase activity.
    Blanco J; Jacotot E; Callebaut C; Krust B; Hovanessian AG
    Adv Exp Med Biol; 1997; 421():193-9. PubMed ID: 9330697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: the pivotal role of vasoactive intestinal peptide.
    Jungraithmayr W; De Meester I; Matheeussen V; Inci I; Augustyns K; Scharpé S; Weder W; Korom S
    Peptides; 2010 Apr; 31(4):585-91. PubMed ID: 20018218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
    Augustyns K; Bal G; Thonus G; Belyaev A; Zhang XM; Bollaert W; Lambeir AM; Durinx C; Goossens F; Haemers A
    Curr Med Chem; 1999 Apr; 6(4):311-27. PubMed ID: 10101215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
    Thompson MA; Ohnuma K; Abe M; Morimoto C; Dang NH
    Mini Rev Med Chem; 2007 Mar; 7(3):253-73. PubMed ID: 17346218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alterations in expression and in serum activity of dipeptidyl peptidase IV (DPP IV, CD26) in patients with hyporectic eating disorders.
    Hildebrandt M; Rose M; Mayr C; Schüler C; Reutter W; Salama A; Klapp BF
    Scand J Immunol; 1999 Nov; 50(5):536-41. PubMed ID: 10564557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence.
    Perner F; Gyuris T; Rákóczy G; Sárváry E; Görög D; Szalay F; Kunos I; Szönyi L; Péterfy M; Takács L
    J Lab Clin Med; 1999 Jul; 134(1):56-67. PubMed ID: 10402060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.